Self funding of phase 2 is a calculated risk in the absense of a satisfactory big pharma deal. Those making sub-standard offers will now have Biota's attention! A successfull phase 2 will up the value by many many times the phase 2 cost and increase the number of competing offers. Perhaps the chance of success is calculated to be very high.